Binding of intracellular anti-Rev single chain variable fragments to different epitopes of human immunodeficiency virus type 1 Rev: Variations in viral inhibition

Journal of Virology

Volumn 70, Issue 5, 1996, Pages 3290-3297

  Wu, Yong ^a   Duan, Lingxun ^a   Zhu, Minghua ^a   Hu, Baocheng ^a   Kubota, Satoshi ^a   Bagasra, Omar ^a   Pomerantz, Roger J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN FRAGMENT; MONOCLONAL ANTIBODY; REV PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0029880867     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.5.3290-3297.1996     Document Type: Article

References (40)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of AIDS-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 59:284-291.
2. Ausubel, F., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1989. Current protocols m molecular biology, vol. 1. John Wiley & Sons. New York
3. Bagasra, O., S. D. Wright, T. Seshamma, J. W. Oakes, and R. J. Pomerantz. 1992. CD14 is involved in control of human immunodeficiency virus type 1 expression in latently-infected cells by lipopolysaccharide. Proc. Natl. Acad. Sci USA 89:6285-6289
4. Bahner, I., Z. Chen, X.-J. Yu, Q.-L. Hao, J. C. Guatelli, and D. B. Kohn. 1993 Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes J. Virol. 67:3199-3207
5. Baltimore, D. 1988. Intracellular immunization. Nature (London) 335:395-396.
6. Bennett, J. C. 1986. Immunoglobulins, and their genes, p. 20-40. In D. J. McCarty (ed.), Arthritis and allied conditions. A textbook of rheumatology. 11th ed. Lea and Febiger, Philadelphia.
7. 6a. Biocca, S., F. Ruberti, M. Tafani, P. Pierandrei-Amaldi, and A. Cattaneo. 1995. Redox state of single chain Fv fragments targeted to the endoplasmic reticulum, cytosol and mitochondria. Bio/Technology 13:1110-1115
8. Bogerd, H. P., R. A. Fridell, S. Madore, and B. R. Cullen. 1995. Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins. Cell 82:485-494
9. Chang, D. D., and P. A. Sharp. 1989. Regulation by HIV Rev depends upon recognition of splice sites. Cell 59:789-795
10. Chen, S. Y., J. Bagley, and W. A. Marasco. 1994 Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum. Gene Ther. 5: 595-601.
11. Duan, L.-X., O. Bagasra, M. A. Laughlin, J. W. Oakes, and R. J. Pomerantz. 1994. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single-chain antibody. Proc. Natl. Acad. Sci. USA 91:5075-5079.
12. Duan, L.-X., J. W. Oakes, A. Ferraro, O. Bagasra, and R. J. Pomerantz. 1994. Tat and Rev differentially affect restricted replication of human immunodeficiency virus type 1 in various cells. Virology 199:474-478.
13. Duan, L.-X., and R. J. Pomerantz. 1994. Elimination of endogenous aberrant kappa chain transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: utility in genetic therapy of HIV-1 infections. Nucleic Acids Res. 22:5433-5438.
14. Duan, L.-X., H. Zhang, J. W. Oakes, O. Bagasra, and R. J. Pomerantz. 1994. Molecular and virological effects of intracellular anti-Rev single chain variable fragment (SFv) on the expression of various HIV-1 strains. Hum. Gene Ther. 5:1315-1324.
15. Duan, L.-X., M. Zhu, O. Bagasra, and R. J. Pomerantz. 1995. Intracellular immunization against HIV-1 infection of human T-lymphocytes: utility of an anti-Rev single chain variable fragments. Hum. Gene Ther. 6:1561-1573.
16. 14a. Feitelson. M. H., M. Zhu, L.-X. Duan, and W. T. London. 1993 Hepatitis B X antigen and p53 are associated in vitro and in liver tissues. Oncogene 8: 1109-1117.
17. Felber, B. K., M. Hadzopoulou-Cladaras, C. Cladaras, T. Copeland, and G. N. Pavlakis. 1989. Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA 86:1495-1499.
18. Fritz, C. C., M. L. Zapp, and M. R. Green. 1995. A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature (London) 376: 530-533.
19. Furuta, R. A., S. Kubota, M. Maki, Y. Miyazaki, T. Hattori, and M. Hatanaka. 1995. Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy. J. Virol. 69:1591-1599.
20. Iverson, A. K. N., E. G. Shaper, A. G. Rodrigo, M. S. Hirsch, B. D. Walker, H. W. Sheppard, T. C. Merigan. and J. I. Mullins. 1995. Persistence of attenuated rev genes in a human immunodeficiency virus type 1-infected asymptomatic individual. J. Virol 69:5743-5753
21. 18a Kubota, S., L. Duan, R. A. Furuta, M. Hatanaka, and R. J. Pomerantz. 1996. Nuclear preservation and cytoplasmic degradation of human immunodeficiency virus type 1 Rev protein. J Virol. 70:1282-1287.
22. Leavitt, M. C., M. Yu, O. Yamada, G. Kraus, D. Looney, E. Poeschla, and F. Wong-Staal. 1994 Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum. Gene Ther. 5:1115-1120.
23. Li, G., J. Lisziewicz, D. Sun, G. Zon, S. Daefler, F. Wong-Staal, R. C. Gallo, and M. E. Klotman. 1993. Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodcoxynucleotide phosphorothioate analogs directed against the Rev-responsive element. J. Virol. 67: 6882-6888.
24. Malim, M. H., S. Bohnlein, J. Hauber, and B. R. Cullen. 1989. Function dissection of the HIV-1 Rev trans-activator: derivation of a trans-dominant repressor of Rev function. Cell 58:205-214.
25. Malim, M. H., J. Hauber, S.-Y. Le, J. V. Maizel, and B. R. Cullen. 1989. The HIV-1 Rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature. 338:254-257.
26. Malim, M. H., D. F. McCarn, L. S. Tiley, and B. R. Cullen. 1991. Mutational definition of the human immunodeficiency virus type 1 Rev activation domain J. Virol. 65:4248-4254.
27. Malim, M. H., L. S. Tiley, D. F. McCarn, J. R. Rusche, J. Hauber, and B. R. Cullen. 1990. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 60:675-683.
28. Marasco, W. A., W. A. Haseltine, and S. Y. Chen. 1993. Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl. Acad. Sci. USA 90:7889-7893.
29. Mhashilkar, A. B., J. Bagley, S. Y. Chen, A. M. Szilvay, D. G. Helland, and W. A. Marasco. 1995, Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 14: 1542-1551.
30. Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniques. 7:980-990.
31. 27a. Minton, A. P. 1990. Holobiochemistry the effect of local environment upon the equilibria and rates of biochemical reactions. Int. J. Biochem. 22:1063-1076.
32. Pomerantz, R. J., T. Seshamma, and D. Trono. 1992. Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J. Virol. 66:1809-1813.
33. Pomerantz, R. J., and D. Trono. 1995. Genetic therapies for HIV infections: promise for the future. AIDS 9:985-993.
34. Sarver, N., E. M. Cantin, P. S. Chang, J. A. Zaia, P. A. Ladne, D. A. Stephens, and J. J. Rossi. 1990. Ribozymes as potential anti-HIV-1 therapeutic agents Science 247:1222-1225.
35. Scharfmann, R., J. H. Axelrod, and I. M. Verma. 1991. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc. Natl. Acad. Sci. USA 88:4626-4630.
36. Strohal, R., G. Groemer, G. Wiek, and R. Kofler. 1987. Complete variable region sequence of a non-functionally rearranged kappa light chain transcribed in the non-secretor P3-X63-Ag8.653 myeloma cell line. Nucleic Acids Res. 15:2771.
37. Sullenger, B. A., H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1990. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63:601-608.
38. Woffendin, C., Z.-Y. Yang, L. Udaykumar, N.-S. Xu, M. J. Yang, D. Sheeny, and G. J. Nabel. 1994. Nonviral and viral delivery of human immunodeficiency virus protective genes into primary human T cells. Proc. Natl. Acad. Sci USA 91:11586-11590.
39. Yu, M., E. Poeschla, and F. Wong-Staal. 1994. Progress towards gene therapy for HIV infection. Gene Ther 1:13-26.
40. Zhang, H., O. Bagasra, M. Niikura, B. J. Poiesz, and R. J. Pomerantz. 1994. Intravirion reverse transcripts in the peripheral blood plasma of human immunodeficiency virus type 1-infected individuals. J Virol. 68:7591-7597.